Although anticancer drugs are widely used to treat cancer, cancer cells can develop resistance to these drugs in various ways, of which P-glycoprotein (P-gp) overexpression is one of the most well-characterised mechanisms of resistance. Identifying mechanisms or drugs to target cancer cells that overexpress P-gp can lead to better outcomes in patients that develop resistance to anticancer drugs. Although P-gp inhibitors for anti-cancer drug combination treatment have been developed, their toxicity in normal cells leads to treatment failure. Considering this, it is therefore important to investigate novel therapeutic options for targeting P-gp overexpressing drug-resistant cancer cells.
In this Research Topic, we aim to identify and investigate novel applications of repositioned drugs for sensitizing P-gp overexpressing resistant cancer cells. Drug repositioning or drug repurposing is the application of known drugs for new indications. It has been used for the treatment of various diseases and has advantages, such as low cost and avoidance of a significant number of toxicity tests which is a time-consuming process. As these drugs are already used in clinical settings, drug repositioning would offer an efficient method to address the urgent need for pharmacological treatment of drug-resistant cancer, allowing the treatment of patients with drug-resistant disease at a relatively fast pace.
We welcome Original Research, Clinical Trial and Review articles including but not limited to the following topics:
1) Drug repositioning for P-glycoprotein overexpressing resistant cancer including products derived from original drugs as well as plant extracts or natural products which have been previously FDA-approved for human use.
2) Pharmacokinetics and pharmacodynamics of drugs with a relatively low half maximal inhibitory concentration (IC50) for a single treatment, when compared to non P-gp overexpressed sensitive (or parents) cancer cells.
3) Pharmacokinetics and pharmacodynamics of drugs with P-gp inhibitory activity for combination treatment with anti-cancer drugs.
4) Pharmacokinetics and pharmacodynamics of drugs with non P-gp inhibitory activity for combination treatment with anti-cancer drugs, in order to minimize any toxic effects due to P-gp inhibition.
Although anticancer drugs are widely used to treat cancer, cancer cells can develop resistance to these drugs in various ways, of which P-glycoprotein (P-gp) overexpression is one of the most well-characterised mechanisms of resistance. Identifying mechanisms or drugs to target cancer cells that overexpress P-gp can lead to better outcomes in patients that develop resistance to anticancer drugs. Although P-gp inhibitors for anti-cancer drug combination treatment have been developed, their toxicity in normal cells leads to treatment failure. Considering this, it is therefore important to investigate novel therapeutic options for targeting P-gp overexpressing drug-resistant cancer cells.
In this Research Topic, we aim to identify and investigate novel applications of repositioned drugs for sensitizing P-gp overexpressing resistant cancer cells. Drug repositioning or drug repurposing is the application of known drugs for new indications. It has been used for the treatment of various diseases and has advantages, such as low cost and avoidance of a significant number of toxicity tests which is a time-consuming process. As these drugs are already used in clinical settings, drug repositioning would offer an efficient method to address the urgent need for pharmacological treatment of drug-resistant cancer, allowing the treatment of patients with drug-resistant disease at a relatively fast pace.
We welcome Original Research, Clinical Trial and Review articles including but not limited to the following topics:
1) Drug repositioning for P-glycoprotein overexpressing resistant cancer including products derived from original drugs as well as plant extracts or natural products which have been previously FDA-approved for human use.
2) Pharmacokinetics and pharmacodynamics of drugs with a relatively low half maximal inhibitory concentration (IC50) for a single treatment, when compared to non P-gp overexpressed sensitive (or parents) cancer cells.
3) Pharmacokinetics and pharmacodynamics of drugs with P-gp inhibitory activity for combination treatment with anti-cancer drugs.
4) Pharmacokinetics and pharmacodynamics of drugs with non P-gp inhibitory activity for combination treatment with anti-cancer drugs, in order to minimize any toxic effects due to P-gp inhibition.
